ISSN: 0004-1963 eISSN: 2217-8767 Journal category: M51 Distinguished National Journal
Development and Validation of an RP-HPLC Method for the Determination of Tiazotic Acid and Its Impurity with Application to Tablet Analysis
Scindeks Assistant SCIndeks Assistant
PDF

How to Cite

1.
Ivković B, Turković N, Turković M, Čudina O, Crevar M. Development and Validation of an RP-HPLC Method for the Determination of Tiazotic Acid and Its Impurity with Application to Tablet Analysis. arhfarm [Internet]. 2026 Apr. 29 [cited 2026 Sep. 19];76(Notebook 2):102-21. Available from: https://test.aseestant.ceon.rs/index.php/arhfarm/article/view/64906

Abstract

A simple and precise RP-HPLC method was developed and validated for the determination of tiazotic acid and its impurity, 3-methyl-1,2,4-triazole-5-thione, with application to tablet analysis. Chromatographic analysis was performed using a Hypersil GOLD aQ C18 column (150 × 4 mm, 3 µm) under isocratic elution conditions with a mobile phase consisting of phosphate buffer (pH 3.3) and methanol in a ratio of 99:1 (v/v), at a flow rate of 1 mL/min and a column temperature of 30 °C. Detection was carried out at 220 nm. The developed method was validated in accordance with ICH guidelines. The following analytical parameters were evaluated during validation: selectivity, linearity, precision, accuracy, robustness, and the limit of quantification (LOQ) for the investigated impurity. The method demonstrated linearity over the concentration range of 0.139–0.238 mg/mL (r = 0.9992) for tiazotic acid and 0.091–1.56 µg/mL (r = 0.9998) for the impurity. Good precision (RSD < 2% for tiazotic acid and RSD < 10% for the impurity), accuracy (recovery in the range of 98–102% and 70–130% for the impurity), and robustness were confirmed. The impurity 3-methyl-1,2,4-triazole-5-thione was detected in tiazotic acid tablets; however, its content was below the limit of quantification (LOQ) of the proposed method (0.091 µg/mL).

Keywords

tiazotic acid
assay
impurity
analytical method validation
HPLC
DOI: 10.5937/arhfarm75-64906

References

Belenichev I, Kucherenko L, Маzur I, Ryzhenko V, Khromylova O, Siusiuka V et al. Thiotriazoline and its today. Dnipro: Jurfond. 2025; 10-23.

Martindale: The Complete Drug Reference. 36th ed. Edited by Sean C. Sweetman, BPharm, FRPharmS. London: Pharmaceutical Press; 2009. Supplementary Drugs and Other Substances, p. 2400.

RU2248353C2. Method for preparing 3‑methyl‑1,2,4‑triazolyl‑5‑thioacetate morpholinium [Internet]. Russian Federation Patent; 2005. [cited 2026 Feb 12]. Available from: https://patents.google.com/patent/RU2248353C2/en#patentCitations.

Ukrainian patent No. 1988, C07D 413/12. Morpholinium 3-methyl-1,2,4-triazolyl-5-thioacetate (thiotriazoline) [Internet]. Ukraine Patent; 1988. [cited 2026 Feb 12]. Available from: https://ukrpatent.org/en/search/main.

Belenichev I, Vizir V, Mamchur V, Kuriata O. Place of Thiotriazolin in the gallery of modern metabolitotropic medicines. Zaporozhye Med J. 2019;1: 118–28.

Taschuk VK, Solobiukova NA, Makarov AA. Effectiveness of thiotriazolin in complex treatment of patients with acute coronary syndrome without ST elevation. Emergency Medicine. 2016; 8(79):35-41.

Salionov VO, Smoilovska HP. The potential of 1,2,4-triazole derivatives as antioxidant agents. Current Issues in Pharmacy and Medicine: Science and Practice. 2025; 8(1):114-118.

Kryvenko VI, Kolesnyk MYu, Bielenichev IF, Pavlov SV. Thiotriazolin effectiveness in complex treatment of patients with post-COVID syndrome. Zaporozhye Med J. 2021; 23(3):402–11.

Pachuta-Stec A. Antioxidant Activity of 1,2,4-Triazole and its Derivatives: A Mini-Review. Mini Rev Med Chem. 2022; 22(7):1081-1094.

Amosova Ye N. Metabolic treatment of myocardial injury associated with ischemia. A new approach to the treatment of coronary heart disease and heart failure. Ukr. Cardiol. Journal. 2000; 4:86-92.

ICH Q2(R2) Guideline on validation of analytical procedures. EMA/CHMP/ICH/82072/2006. Committee for Medicinal Products for Human Use [Internet]. EMA; 2023. [cited 2026 Feb 13]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q2r2-guideline-validation-analytical-procedures-step-5-revision-1_en.pdf.

Autori koji objavljuju u ovom časopisu pristaju na sledeće uslove:

  1. Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.

  2. Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.

  3. Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).